Aprogen Biologics Inc. (KRX:003060)
South Korea · Delayed Price · Currency is KRW 236.00
+1.00 (0.43%)
At close: Apr 8, 2026
Aprogen Biologics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 73,226 | 67,378 | 87,364 | 65,190 | 56,482 |
Other Revenue | 0 | - | - | - | - |
| 73,226 | 67,378 | 87,364 | 65,190 | 56,482 | |
Revenue Growth (YoY) | 8.68% | -22.88% | 34.01% | 15.42% | 5.93% |
Cost of Revenue | 100,580 | 75,224 | 99,337 | 39,380 | 31,607 |
Gross Profit | -27,354 | -7,846 | -11,974 | 25,810 | 24,875 |
Selling, General & Admin | 28,056 | 26,343 | 29,789 | 28,914 | 25,947 |
Research & Development | 4,003 | 18,035 | 15,000 | 2,187 | 1,735 |
Amortization of Goodwill & Intangibles | 0.76 | 13.93 | 19.46 | 45.8 | 133.95 |
Other Operating Expenses | 576.4 | 383.38 | 357.6 | 365.27 | 416.95 |
Operating Expenses | 95,536 | 50,730 | 58,716 | 30,015 | 28,850 |
Operating Income | -122,889 | -58,577 | -70,690 | -4,204 | -3,975 |
Interest Expense | -10,700 | -5,514 | -3,668 | -274.41 | -31.14 |
Interest & Investment Income | 9,875 | 4,242 | 4,488 | 16,645 | 13,587 |
Earnings From Equity Investments | -285.5 | 19,018 | 79,786 | 94.73 | 352.2 |
Currency Exchange Gain (Loss) | 242.83 | -20.53 | -6.22 | 33.16 | 12.72 |
Other Non Operating Income (Expenses) | 42,741 | -10,015 | 564.26 | 209.78 | 347.85 |
EBT Excluding Unusual Items | -81,016 | -50,865 | 10,474 | 12,504 | 10,294 |
Gain (Loss) on Sale of Investments | -86,707 | -57,999 | 29,950 | 2,638 | 1,623 |
Gain (Loss) on Sale of Assets | 88.69 | 16.15 | -151,537 | 3.1 | 53.08 |
Asset Writedown | -637.76 | -154.08 | -2,271 | -264.15 | -2,134 |
Other Unusual Items | -1,106 | 4,023 | - | -1.04 | -4.76 |
Pretax Income | -169,378 | -104,980 | -113,383 | 14,881 | 9,831 |
Income Tax Expense | -1,081 | - | 1,947 | 1,260 | 679.69 |
Earnings From Continuing Operations | -168,297 | -104,980 | -115,330 | 13,621 | 9,151 |
Minority Interest in Earnings | -2,034 | 0.72 | -2,940 | -981.32 | -1,048 |
Net Income | -170,331 | -104,979 | -118,270 | 12,639 | 8,103 |
Net Income to Common | -170,331 | -104,979 | -118,270 | 12,639 | 8,103 |
Net Income Growth | - | - | - | 55.99% | -27.99% |
Shares Outstanding (Basic) | 198 | 126 | 63 | 40 | 40 |
Shares Outstanding (Diluted) | 198 | 126 | 63 | 40 | 40 |
Shares Change (YoY) | 57.17% | 99.30% | 56.07% | 1.42% | 25.52% |
EPS (Basic) | -862.00 | -835.00 | -1874.81 | 312.69 | 203.29 |
EPS (Diluted) | -862.00 | -835.00 | -1875.00 | 310.00 | 200.00 |
EPS Growth | - | - | - | 55.00% | -42.86% |
Free Cash Flow | -47,857 | -46,261 | -61,739 | 24,444 | -7,023 |
Free Cash Flow Per Share | -242.19 | -367.96 | -978.68 | 604.74 | -176.20 |
Gross Margin | -37.35% | -11.64% | -13.71% | 39.59% | 44.04% |
Operating Margin | -167.82% | -86.94% | -80.92% | -6.45% | -7.04% |
Profit Margin | -232.61% | -155.81% | -135.38% | 19.39% | 14.34% |
Free Cash Flow Margin | -65.36% | -68.66% | -70.67% | 37.50% | -12.43% |
EBITDA | -103,705 | -39,486 | -49,292 | -1,800 | -1,903 |
EBITDA Margin | -141.62% | -58.60% | -56.42% | -2.76% | -3.37% |
D&A For EBITDA | 19,185 | 19,090 | 21,398 | 2,404 | 2,072 |
EBIT | -122,889 | -58,577 | -70,690 | -4,204 | -3,975 |
EBIT Margin | -167.82% | -86.94% | -80.92% | -6.45% | -7.04% |
Effective Tax Rate | - | - | - | 8.47% | 6.91% |
Advertising Expenses | 445.33 | 521.48 | 736.69 | 1,371 | 7,800 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.